Nehal Lakhani is an Oncology physician. ClinicalTrials.gov lists 4 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
5800 Foremost Dr SE Ste 100
Grand Rapids, MI 495467062
Telephone
616-954-5554Provider last certified this registry record 13 Mar 2020.
Clinical trials
- S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
Sponsor: Institut de Recherches Internationales Servier
- AVID100 in Advanced Epithelial Carcinomas
Sponsor: Formation Biologics
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Janssen Global Services, LLCProgram year20251 payment
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20251 payment
- GlaxoSmithKline, LLC.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Sensory organs
51.8%Corticosteroid51.8%Dexamethasone sodium phosphate100%Part B, office-administered≥28 patientsMetabolism & gastrointestinal
39.9%Serotonin-3 Receptor Antagonist38.1%Palonosetron hcl52%Granisetron hydrochloride49%Part B, office-administered≥14 patientsAntidiarrheal1%Diphenoxylate-Atropine100%Part D<11 patients+ 1 more class in this area
Respiratory
4.7%Histamine-1 Receptor Antagonist3.7%Diphenhydramine hcl100%Part B, office-administered≥23 patientsOpioid Agonist1%Hydrocodone-Acetaminophen100%Part D≥12 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”